About Recce Limited
Recce Limited (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as RECCE® 327 is being developed for the treatment of sepsis derived from S. aureus and E. coli bacteria including their superbug forms. Recce has a manufacturing facility in Australia and clinical research partners in the USA. It has validated an automated process to manufacture its lead compound ahead of first-in-man clinical trials.